SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-23-024004
Filing Date
2023-05-11
Accepted
2023-05-11 07:24:18
Documents
14
Period of Report
2023-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc20052771_8k.htm   iXBRL 8-K 31277
2 EXHIBIT 99.1 brhc20052771_ex99-1.htm EX-99.1 126804
6 image00004.jpg GRAPHIC 7225
  Complete submission text file 0001140361-23-024004.txt   323012

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA atai-20230511.xsd EX-101.SCH 3856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE atai-20230511_lab.xml EX-101.LAB 23290
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE atai-20230511_pre.xml EX-101.PRE 16546
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc20052771_8k_htm.xml XML 4214
Mailing Address 524 BROADWAY NEW YORK NY 10013
Business Address WALLSTRASSE 16 BERLIN 2M 10179 (617)-699-5876
ATAI Life Sciences N.V. (Filer) CIK: 0001840904 (see all company filings)

IRS No.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40493 | Film No.: 23908818
SIC: 2834 Pharmaceutical Preparations